News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News Laquinimod failure is bad news for Teva's MS hopes Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.
News AZ hopes to boost respiratory pipeline with Pieris deal AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.
News FDA approves Teva's Huntington's Disease drug First treatment approved for Huntington's Disease in almost a decade.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
